It Seems KemPharm Inc (KMPH) Will Go Up. Have Another Big Increase

September 17, 2017 - By Winifred Garcia

The stock of KemPharm Inc (NASDAQ:KMPH) is a huge mover today! The stock increased 5.97% or $0.2 on September 15, reaching $3.55. About 110,033 shares traded or 18.21% up from the average. KemPharm Inc (NASDAQ:KMPH) has declined 32.16% since September 17, 2016 and is downtrending. It has underperformed by 48.86% the S&P500.
The move comes after 6 months positive chart setup for the $52.03M company. It was reported on Sep, 17 by Barchart.com. We have $3.87 PT which if reached, will make NASDAQ:KMPH worth $4.68M more.

Investors wait KemPharm Inc (NASDAQ:KMPH) to report on November, 8. its quarterly earnings Wall Street analysts expect $-0.69 EPS, up $0.23 or 25.00 % from last year’s $-0.92 same quarter earnings. KemPharm Inc’s Wall Street analysts see 56.82 % negative EPS growth, taking into account the $-0.44 EPS reproted in the previous quarter,

KemPharm Inc (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 14 analyst reports since August 14, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, May 6 by RBC Capital Markets. The stock of KemPharm Inc (NASDAQ:KMPH) earned “Buy” rating by Canaccord Genuity on Thursday, August 10. Oppenheimer maintained the stock with “Buy” rating in Thursday, August 10 report. The stock of KemPharm Inc (NASDAQ:KMPH) earned “Outperform” rating by Oppenheimer on Friday, September 18. As per Thursday, September 17, the company rating was maintained by Canaccord Genuity. The stock of KemPharm Inc (NASDAQ:KMPH) has “Buy” rating given on Tuesday, December 20 by Canaccord Genuity. Canaccord Genuity maintained the stock with “Buy” rating in Monday, September 11 report. Roth Capital maintained it with “Buy” rating and $800 target in Friday, August 11 report. The rating was initiated by Roth Capital with “Buy” on Wednesday, June 28. The stock has “Buy” rating by Oppenheimer on Wednesday, June 28.

More notable recent KemPharm Inc (NASDAQ:KMPH) news were published by: Prnewswire.com which released: “Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics …” on October 26, 2016, also Globenewswire.com with their article: “KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and …” published on March 27, 2017, Marketwatch.com published: “3.60” on April 16, 2015. More interesting news about KemPharm Inc (NASDAQ:KMPH) were released by: Globenewswire.com and their article: “KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results” published on February 28, 2017 as well as Globenewswire.com‘s news article titled: “KemPharm Announces FDRR Process Completion and Resubmission of the Apadazâ„¢ NDA” with publication date: September 12, 2017.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The company has market cap of $52.03 million. The Firm is engaged in the discovery and development of prodrugs. It currently has negative earnings. The Firm uses its Ligand Activated Therapy platform technology to create prodrugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.